

13th July, 2017

BSE Limited Corporate Relations Department P J Towers, Dalal Street Mumbai 400 001 <u>Scrip Code: 532300</u> Fax Nos: 22723121	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai 400 051. <u>NSE Symbol – WOCKPHARMA</u> <u>Fax Nos: 26598237 / 26598238</u>
--	---

Dear Sirs,

Sub: Compliance Report on Corporate Governance

In compliance with Regulation 27(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Compliance Report on Corporate Governance for the quarter ended 30th June, 2017.

Kindly acknowledge receipt of the same.

Thanking you,

For **Wockhardt Limited**



Narendra Singh
Company Secretary



Encl: As above



1. Name of Listed Entity : Wockhardt Limited
2. Quarter ending : 30th June, 2017

I. Composition of Board of Directors

Title (Mr. / Ms)	Name of the Director	PAN & DIN		Category (Chairperson/Executive/Non-Executive/Independent/Nominee) &	Date of Appointment In the current term	Tenure*	No. of Directorship in listed entities including this listed entity	Number of memberships in Audit/ Stakeholder Committee(s) Including this listed entity	No. of post of Chairperson in Audit/ Stakeholder Committee held in listed entities Including this listed entity
		PAN	DIN						
Dr.	Habil F Khorakiwala	AABPK4415C	00045608	Chairperson- Executive	01.03.2015	29.02.2020	1	0	0
Dr.	Huzaila H Khorakiwala	ABLPK6715C	02191870	Executive	31.03.2014	30.03.2019	1	1	0
Dr.	Murtaza H Khorakiwala	AAZPK7040H	00102650	Managing Director-Executive	31.03.2014	30.03.2019	1	0	1
Mr.	Shekhar Datta	AABPD6228L	00045591	Non-Executive Independent	01.04.2014	Upto 31.03.2019	4	2	2
Dr.	Sanjaya Baru	AAFPB4429H	05344208	Non-Executive Independent	01.04.2014		1	3	0
Mr.	Aman Mehta	AAGPM5030J	00009364	Non-Executive Independent	01.04.2014		6	5	1
Mr.	D S Brar	AAGPB0665A	00068502	Non-Executive Independent	01.04.2014		3	6	1
Ms.	Tasneem Mehta	AAAPZ1346C	05009664	Non-Executive Independent	30.09.2014	Upto 29.09.2019	1	2	0
Mr.	Baldev Raj Arora	AAAPA5988R	00194168	Non-Executive Independent	28.05.2015	Upto 27.05.2020	2	2	0
Mr.	Vinesh Kumar Jairath	AAYPJ0756C	00391684	Non-Executive Independent	10.11.2016	Upto 09.11.2021	4	6	3

*Filled only for Independent Directors

II. Composition of Committees

Name of Committee	Name of Committee members	Category (Chairperson/Executive/Non-Executive/Independent/Nominee)
1. Audit Committee	Mr. Shekhar Datta	Chairman- Non-Executive Independent
	Mr. Aman Mehta	Non-Executive Independent
	Mr. D S Brar	Non-Executive Independent
	Dr. Sanjaya Baru	Non-Executive Independent
	Ms. Tasneem Mehta	Non-Executive Independent
	Mr. Baldev Raj Arora	Non-Executive Independent
	Mr. Vinesh Kumar Jairath	Non-Executive Independent
2. Nomination & Remuneration Committee	Mr. Shekhar Datta	Chairman- Non-Executive Independent
	Dr. Habil F. Khorakiwala	Executive
	Dr. Sanjaya Baru	Non-Executive Independent
3. Risk Management Committee	N.A.	N.A.
4. Stakeholders Relationship Committee	Mr. Shekhar Datta	Chairman- Non-Executive Independent
	Mr. Aman Mehta	Non-Executive Independent
	Mr. D S Brar	Non-Executive Independent
	Dr. Sanjaya Baru	Non-Executive Independent
	Ms. Tasneem Mehta	Non-Executive Independent
	Mr. Baldev Raj Arora	Non-Executive Independent
	Mr. Vinesh Kumar Jairath	Non-Executive Independent

III. Meeting of Board of Directors

Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Maximum gap between any two consecutive (in number of days)
24.01.2017	04.05.2017	99 (excluding date of meetings)

IV. Meeting of Committees**

Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (details)	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings in number of days
04.05.2017	Yes	24.01.2017	99 (excluding date of meetings)

** Details provided only for Audit Committee

V. Related Party Transactions

Subject	Compliance status (Yes/No/NA)
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT@	Yes
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes

@Transactions with Wockhardt Bio AG are considered material and approval of Shareholders has been obtained at the Annual General Meeting held on 15th September, 2014.

VI. Affirmations

- The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015. - Yes
 - The composition of the following committees is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015
 - Audit Committee - Yes
 - Nomination & remuneration committee - Yes
 - Stakeholders relationship committee - Yes
 - Risk Management Committee - N.A.
 - The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015 - Yes
 - The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. - Yes
- This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Any comments/observations/advice of Board of Directors may be mentioned here:
- The Report for quarter ended 31st March, 2017 was placed before the Board of Directors at their meeting held on 4th May, 2017.
 - This Report for the quarter ended 30th June, 2017 shall be placed before the Board at the ensuing Board Meeting.

Narendra Singh
Company Secretary

13th July 2017



WOCKHARDT LIMITED**DETAILS OF MATERIAL RELATED PARTY TRANSACTIONS FOR THE
QUARTER ENDED 30th JUNE, 2017**

Name of Related Party	Name of transaction	Amount of transaction for the quarter ended 30th June, 2017 (Rs. in crores) (Unaudited)
Wockhardt Bio AG (Subsidiary Company)	Outlicensing Fees	-
	R&D service	7.78
	Guarantee Fees Income	3.87
	Management Fees	0.60
	Sales of finished goods	66.06
	Expenses recovered	0.08
	Expenses reimbursed	0.12
	Advances received against export for goods & services	-
	Advances adjusted against export for goods & services	22.53
	Total	101.04

